Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury
About this trial
This phase I trial is enrolling 36 participants with chronic spinal cord injury to assess the safety, tolerability, and effect of a drug - EC5026 - on neuropathic pain. If included, participants will be randomly assigned to receive the drug or a placebo once daily for 14 consecutive days. Final testing of safety, tolerability, and changes in pain will be performed after 30 days.
Included participants
What’s involved
Type
Details
- Participants will receive a drug (EC5026) or a placebo once daily for 14 consecutive days. - Final testing of safety and tolerability will be performed after 30 days.
Potential benefits
Main benefits
General health
Additional benefits
Pain
Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.
Wings for Life supports SCITrialsFinder
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more- Trial recruitment status
- Recruiting soon
- Trial start date
- 1 Dec 2024
- Organisation
- EicOsis Human Health Inc.
- Trial recruitment status
- Recruiting soon
- Trial start date
- 1 Dec 2024
- Organisation
- EicOsis Human Health Inc.
About this trial
Included participants
What’s involved
Potential benefits
Wings for Life supports SCITrialsFinder
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more